| Literature DB >> 15850462 |
Abstract
The combination of pegylated interferon alpha and ribavirin has improved treatment success rates in patients with hepatitis C with sustained response rates of just over 50% overall and more than 70% for those with genotypes 2 and 3. This article reviews the use of combination therapy, contraindications, factors influencing response and describes approaches to specific patient groups.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15850462 DOI： 10.1111/j.1365-2893.2005.00600.x
Source DB: PubMed Journal: J Viral Hepat ISSN： 1352-0504 Impact factor: 3.728